191 related articles for article (PubMed ID: 31822786)
1. Ambroxol improves skeletal and hematological manifestations on a child with Gaucher disease.
Jiang W; Yi M; Maegawa GHB; Zhang H
J Hum Genet; 2020 Mar; 65(3):345-349. PubMed ID: 31822786
[TBL] [Abstract][Full Text] [Related]
2. Ambroxol Chaperone Therapy for Gaucher Disease Type I-Associated Liver Cirrhosis and Portal Hypertension: A Case Report.
Zhang P; Zheng MF; Cui SY; Zhang W; Gao RP
Endocr Metab Immune Disord Drug Targets; 2022; 22(6):658-662. PubMed ID: 34802413
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy.
Kim YM; Yum MS; Heo SH; Kim T; Jin HK; Bae JS; Seo GH; Oh A; Yoon HM; Lim HT; Kim HW; Ko TS; Lim HS; Osborn MJ; Tolar J; Cozma C; Rolfs A; Zimran A; Lee BH; Yoo HW
J Med Genet; 2020 Feb; 57(2):124-131. PubMed ID: 31649052
[TBL] [Abstract][Full Text] [Related]
4. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells.
McNeill A; Magalhaes J; Shen C; Chau KY; Hughes D; Mehta A; Foltynie T; Cooper JM; Abramov AY; Gegg M; Schapira AH
Brain; 2014 May; 137(Pt 5):1481-95. PubMed ID: 24574503
[TBL] [Abstract][Full Text] [Related]
5. Gaucher disease.
Mignot C; Gelot A; De Villemeur TB
Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
[TBL] [Abstract][Full Text] [Related]
6. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
7. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase.
Bendikov-Bar I; Maor G; Filocamo M; Horowitz M
Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495
[TBL] [Abstract][Full Text] [Related]
8. Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data.
Istaiti M; Revel-Vilk S; Becker-Cohen M; Dinur T; Ramaswami U; Castillo-Garcia D; Ceron-Rodriguez M; Chan A; Rodic P; Tincheva RS; Al-Hertani W; Lee BH; Yang CF; Kiec-Wilk B; Fiumara A; Rubio B; Zimran A
Am J Hematol; 2021 May; 96(5):545-551. PubMed ID: 33606887
[TBL] [Abstract][Full Text] [Related]
9. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.
Ramadža DP; Zekušić M; Žigman T; Škaričić A; Bogdanić A; Mustać G; Bošnjak-Nađ K; Ozretić D; Ohno K; Fumić K; Barić I
Eur J Paediatr Neurol; 2021 May; 32():66-72. PubMed ID: 33836415
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease.
Maegawa GH; Tropak MB; Buttner JD; Rigat BA; Fuller M; Pandit D; Tang L; Kornhaber GJ; Hamuro Y; Clarke JT; Mahuran DJ
J Biol Chem; 2009 Aug; 284(35):23502-16. PubMed ID: 19578116
[TBL] [Abstract][Full Text] [Related]
11. Rapid and long-lasting efficacy of high-dose ambroxol therapy for neuronopathic Gaucher disease: A case report and literature review.
Higashi K; Sonoda Y; Kaku N; Fujii F; Yamashita F; Lee S; Tocan V; Ebihara G; Matsuoka W; Tetsuhara K; Sonoda M; Chong PF; Mushimoto Y; Kojima-Ishii K; Ishimura M; Koga Y; Fukuta A; Tsuchihashi NA; Kikuchi Y; Karashima T; Sawada T; Hotta T; Yoshimitsu M; Terazono H; Tajiri T; Nakagawa T; Sakai Y; Nakamura K; Ohga S
Mol Genet Genomic Med; 2024 Apr; 12(4):e2427. PubMed ID: 38553911
[TBL] [Abstract][Full Text] [Related]
12. Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism.
Kopytova AE; Rychkov GN; Nikolaev MA; Baydakova GV; Cheblokov AA; Senkevich KA; Bogdanova DA; Bolshakova OI; Miliukhina IV; Bezrukikh VA; Salogub GN; Sarantseva SV; Usenko TC; Zakharova EY; Emelyanov AK; Pchelina SN
Parkinsonism Relat Disord; 2021 Mar; 84():112-121. PubMed ID: 33609962
[TBL] [Abstract][Full Text] [Related]
13. A comparative computational approach toward pharmacological chaperones (NN-DNJ and ambroxol) on N370S and L444P mutations causing Gaucher's disease.
Thirumal Kumar D; Iyer S; Christy JP; Siva R; Tayubi IA; George Priya Doss C; Zayed H
Adv Protein Chem Struct Biol; 2019; 114():315-339. PubMed ID: 30635084
[TBL] [Abstract][Full Text] [Related]
14. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
15. High risk screening for Gaucher disease in patients with splenomegaly and/or thrombocytopenia in China: 55 cases identified.
Huang Y; Jia X; Tang C; Liu S; Sheng H; Zhao X; Zeng C; Liu L
Clin Chim Acta; 2020 Jul; 506():22-27. PubMed ID: 32165122
[TBL] [Abstract][Full Text] [Related]
16. Three mutations of adult type 1 Gaucher disease found in a Chinese patient: A case report.
Du X; Ding Q; Chen Q; Guo P; Wang Q
Medicine (Baltimore); 2018 Nov; 97(47):e13161. PubMed ID: 30461613
[TBL] [Abstract][Full Text] [Related]
17. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).
Hruska KS; LaMarca ME; Scott CR; Sidransky E
Hum Mutat; 2008 May; 29(5):567-83. PubMed ID: 18338393
[TBL] [Abstract][Full Text] [Related]
18. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.
Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D
Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808
[TBL] [Abstract][Full Text] [Related]
19. Genotype/phenotype relationship in Gaucher disease patients. Novel mutation in glucocerebrosidase gene.
Lepe-Balsalobre E; Santotoribio JD; Nuñez-Vazquez R; García-Morillo S; Jiménez-Arriscado P; Hernández-Arévalo P; Delarosa-Rodríguez R; Guerrero JM; Macher HC
Clin Chem Lab Med; 2020 Jun; 58(12):2017-2024. PubMed ID: 32589593
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.
Baris HN; Cohen IJ; Mistry PK
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1(0 1):72-81. PubMed ID: 25345088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
